Day: April 24, 2025

First Merchants Corporation Announces First Quarter 2025 Earnings Per Share

Written by Customer Service on April 24, 2025. Posted in Earnings Releases And Operating Results.

MUNCIE, Ind., April 24, 2025 (GLOBE NEWSWIRE) — First Merchants Corporation (NASDAQ – FRME) First Quarter 2025 Highlights:Net income available to common stockholders was $54.9 million and diluted earnings per common share totaled $0.94 compared to adjusted net income and diluted earnings per common share1 of $50.1 million and $0.85 in the first quarter of 2024. Adjusted net income and diluted earnings per common share1 in the fourth quarter of 2024 were $58.1 million and $1.00, respectively. Robust capital position with Common Equity Tier 1 Capital Ratio of 11.50%. Repurchased 246,751 shares totaling $10 million year-to-date; Redeemed $30 million of sub debt. Total loans grew $154.9 million, or 4.8% annualized, on a linked quarter basis, and $547.2 million, or 4.4%, during the last twelve months. Total deposits declined...

Independent Bank Corporation Reports 2025 First Quarter Results

Written by Customer Service on April 24, 2025. Posted in Earnings Releases And Operating Results.

First Quarter Highlights Highlights for the first quarter of 2025 include:Increase in net interest income of $0.8 million (or 1.9% ) over the fourth quarter of 2024; Increase in tangible book value per share of $2.43 (13.2%) from March 31, 2024; Net growth in core deposits of $9.1 million (or 0.8% annualized) from December 31, 2024; Net growth in loans of $33.9 million (or 3.4% annualized) from December 31, 2024; and The payment of a 26 cent per share dividend on common stock on February 14, 2025.GRAND RAPIDS, Mich., April 24, 2025 (GLOBE NEWSWIRE) — Independent Bank Corporation (NASDAQ: IBCP) reported first quarter 2025 net income of $15.6 million, or $0.74 per diluted share, versus net income of $16.0 million, or $0.76 per diluted share, in the prior-year period. William B. (“Brad”) Kessel, the President and Chief Executive...

Correction: Form 8.3 – Warehouse REIT Plc

Written by Customer Service on April 24, 2025. Posted in Mergers And Acquisitions.

8.3 PUBLIC OPENING POSITION DISCLOSURE/DEALING DISCLOSURE BY A PERSON WITH INTERESTS IN RELEVANT SECURITIES REPRESENTING 1% OR MORERule 8.3 of the Takeover Code (the “Code”) 1. KEY INFORMATION(a) Full name of discloser: Rathbones Group Plc(b) Owner or controller of interests and short positions disclosed, if different from 1(a): The naming of nominee or vehicle companies is insufficient. For a trust, the trustee(s), settlor and beneficiaries must be named. (c) Name of offeror/offeree in relation to whose relevant securities this form relates: Use a separate form for each offeror/offeree Warehouse REIT Plc(d) If an exempt fund manager connected with an offeror/offeree, state this and specify identity of offeror/offeree: (e) Date position held/dealing undertaken: For an opening position...

Esperion Unveils Promising Research Supporting Lead Development Candidates for Primary Sclerosing Cholangitis (PSC) at R&D Day 2025

Written by Customer Service on April 24, 2025. Posted in Public Companies.

– Expands Development Portfolio with Introduction of a Novel Program Targeting PSC – – Confirms Highly Specific Allosteric ACLY Inhibitor Shown to Reduce Liver Injury, Inflammation and Fibrosis Across Multiple PSC-Relevant Pre-Clinical Models – – Demonstrates Internal R&D Capabilities with Wholly Owned, Next-Generation Candidates Targeting Liver and Kidney Disease – – Esperion to Webcast R&D Day Event Today at 9:00 a.m. ET – ANN ARBOR, Mich., April 24, 2025 (GLOBE NEWSWIRE) — Esperion (NASDAQ: ESPR) today announced that the Company plans to highlight new research supporting its lead development candidates for the treatment of primary sclerosing cholangitis (PSC), a rare and progressive liver disease, today at 9:00 a.m. ET in New York City. A live webcast of the event will also be available. These candidates are novel...

NevGold Discovers More Significant Oxide Gold-Antimony Results: 2.11 g/t AuEq Over 67.1 Meters (1.30 g/t Au And 0.18% Antimony), Including 4.29 g/t AuEq Over 30.5 Meters (2.79 g/t Au And 0.33% Antimony), and Also Including 7.12 g/t AuEq Over 16.8 Meters (5.05 g/t Au And 0.46% Antimony) at the Limousine Butte Project, Nevada

Written by Customer Service on April 24, 2025. Posted in Public Companies.

Vancouver, British Columbia, April 24, 2025 (GLOBE NEWSWIRE) — NevGold Corp. (“NevGold” or the “Company”) (TSXV:NAU) (OTCQX:NAUFF) (Frankfurt:5E50) is pleased to announce that it has discovered further significant oxide gold-antimony (“Antimony”, “Sb”) drill results at its Limousine Butte Project (the “Project”, “Limo Butte”) in Nevada. The Company continues to unlock the substantial gold-antimony potential of the Project, highlighting its promising prospects for further exploration and development in Nevada, one of the world’s prolific mining jurisdictions.Key HighlightsFurther positive, near-surface, oxide gold-antimony historical drillholes at Resurrection Ridge include: LB023: 2.11 g/t AuEq* over 67.1 meters (1.30 g/t Au and 0.18% Sb), including 4.29 g/t AuEq* over 30.5 meters (2.79 g/t Au and 0.33% Sb), and also including...

Krystal Biotech to Present at Upcoming Scientific Conferences

Written by Customer Service on April 24, 2025. Posted in Public Companies.

PITTSBURGH, April 24, 2025 (GLOBE NEWSWIRE) — Krystal Biotech, Inc. (the “Company”) (NASDAQ: KRYS) announced today that the Company will be presenting on multiple programs in the lung, eye, and skin at upcoming scientific conferences being held in May and June. Presentation details are outlined below. American Society of Gene & Cell Therapy (ASGCT) 28th Annual MeetingInvited Oral PresentationTitle: HSV-1 as a vector system for targeting respiratory tissues in genetic pulmonary disease Presenter: Trevor Parry, PhD Date and Time: May 17, 2025 at 8:50AM CT2025 American Society of Clinical Oncology (ASCO) Annual MeetingPoster PresentationTitle: Inhaled KB707, a novel HSV-based immunotherapy, as a monotherapy in patients with advanced solid tumor malignancies affecting the lungs: Efficacy and safety results from a phase 1/2...

Cidara Therapeutics to Report First Quarter 2025 Financial Results and Host Inaugural Quarterly Conference Call on May 8, 2025

Written by Customer Service on April 24, 2025. Posted in Public Companies.

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) — Cidara Therapeutics, Inc. (Nasdaq: CDTX), a biotechnology company using its proprietary Cloudbreak® platform to develop drug-Fc conjugate (DFC) immunotherapies, today announced that it will report its first quarter 2025 financial results and operational highlights after the close of the U.S. financial markets on Thursday, May 8, 2025. The Company will host a conference call and webcast at 5:00 PM Eastern Time to discuss the results and provide an update on business operations. Conference Call Dial-In & Webcast InformationDate: Thursday, May 8, 2025Time: 5:00 PM Eastern TimeUnited States: 1-800-717-1738International: 1-646-307-1865Conference ID: 90743Webcast: Link About Cidara TherapeuticsCidara Therapeutics is using its proprietary Cloudbreak® platform...

BioAtla Announces Poster Presentations at the 2025 American Association for Cancer Research (AACR) Annual Meeting

Written by Customer Service on April 24, 2025. Posted in Public Companies.

SAN DIEGO, April 24, 2025 (GLOBE NEWSWIRE) — BioAtla, Inc. (Nasdaq: BCAB), a global clinical-stage biotechnology company focused on the development of Conditionally Active Biologic (CAB) antibody therapeutics for the treatment of solid tumors, today announced preclinical poster presentations at the upcoming 2025 American Association for Cancer Research (AACR) to be held at the McCormick Place Convention Center in Chicago, IL from April 25–30, 2025. Two abstracts accepted for poster presentation highlight Company’s proprietary Conditionally Active Biologic (CAB) technology Differentiated preclinical activity for CAB anti-Nectin4-antibody drug conjugate (ADC) with superior efficacy to enfortumab vedotin analogue in lung, breast, pancreatic and urothelial patient derived cancer models CAB technology provides a new generation of...

Brera Holdings Portfolio Club Juve Stabia “The Second Team of Naples” Achieves Highest Market Value Increase in Serie B

Written by Customer Service on April 24, 2025. Posted in Public Companies.

Juve Stabia’s squad value has risen 36.9%, from €11.78M to €16.13M, as the team climbs to 5th in Serie BJuve Stabia’s squad value has risen 36.9%, from €11.78M to €16.13M, as the team climbs to 5th in Serie BJuve Stabia’s squad value has risen 36.9%, from €11.78M to €16.13M, as the team climbs to 5th in Serie B Dublin, Ireland and Milan, Italy, April 24, 2025 (GLOBE NEWSWIRE) — Brera Holdings PLC (“Brera Holdings” or the “Company”) (Nasdaq: BREA), an Ireland-based international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership (“MCO”) strategy, is proud to announce that S.S. Juve Stabia S.r.l., “The Second Team of Naples” and a Brera Holdings portfolio club (“Juve Stabia”), has recorded the highest market value increase in Italy’s Serie B over the...

Cocrystal Pharma’s Norovirus Oral Antiviral Candidate Demonstrates Potent Activity Against the Emerging GII.17 Variants

Written by Customer Service on April 24, 2025. Posted in Public Companies.

Norovirus GII.17 variants have overtaken GII.4 as the most prevalent strain and significantly increased norovirus outbreaks in the U.S. and European countries in 2024-2025 Cocrystal Pharma’s pan-viral protease inhibitor CDI-988 shows superior broad-spectrum antiviral activity against major norovirus variants including GII.4 and GII.17 strains Company reported favorable safety and tolerability of CDI-988 in Phase 1 and plans to initiate a human challenge study in 2025 for the treatment and prevention of norovirus infectionBOTHELL, Wash., April 24, 2025 (GLOBE NEWSWIRE) — Cocrystal Pharma, Inc. (Nasdaq: COCP) (“Cocrystal” or the “Company”) announces that its investigative drug candidate CDI-988 was shown to bind to the highly conserved region of the GII.17 protease with excellent potency, similar to that shown across a range of...

Day: April 24, 2025

Disclaimer & Cookie Notice

Welcome to GOLDEA services for Professionals